Current recommendations and recent progress in endometrial cancer

Rebecca A. Brooks, Gini F. Fleming, Ricardo R. Lastra, Nita K. Lee, John W. Moroney, Christina H. Son, Ken Tatebe, Jennifer L. Veneris

Research output: Contribution to journalReview articlepeer-review

Abstract

Endometrial cancer is the most common gynecologic cancer in the United States, and its incidence is rising. Although there have been significant recent advances in our understanding of endometrial cancer biology, many aspects of treatment remain mired in controversy, including the role of surgical lymph node assessment and the selection of patients for adjuvant radiation or chemotherapy. For the subset of women with microsatellite-instable, metastatic disease, anti– programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.

Original languageEnglish (US)
Pages (from-to)258-279
Number of pages22
JournalCA Cancer Journal for Clinicians
Volume69
Issue number4
DOIs
StatePublished - Jul 1 2019

Keywords

  • endometrial cancer
  • health disparities
  • microsatellite instability
  • uterine cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Current recommendations and recent progress in endometrial cancer'. Together they form a unique fingerprint.

Cite this